Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=300&ordering=begin_effective
{ "count": 2244, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=320&ordering=begin_effective", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=280&ordering=begin_effective", "results": [ { "id": 1721, "title": { "de": "Influence of Resveratrol, Quercetin-dihydrate und Seleno-L-Methoionine an Matrix Metalloproteinases and RANKL Levels in Human Osteoarthritis Rheumatoid Arthritis Synovial Fluids", "en": "Influence of Resveratrol, Quercetin-dihydrate und Seleno-L-Methoionine an Matrix Metalloproteinases and RANKL Levels in Human Osteoarthritis Rheumatoid Arthritis Synovial Fluids" }, "short": "Metalloproteinases and RANKL Levels ", "url": null, "abstract": { "de": "Osteoarthritis (OA) is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on special inflammation enzymes and factors in human synovial fluid. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial fluid. If the protective potency on Osteoarthritis is similar to the results of animal experiments, it would be an enormous effort. Previous studies indicate that elevated levels of matrix metalloproteinases (MMPs) and receptor activator of nuclear factor NFkB ligand (RANKL) play an important role in cartilage degeneration in OA Rheumatic Arthritis (RA) and Psoriatic Arthritis (PsA) [1, 2]. \r\nThis study should be undertaken to define a possible influence of Resveratrol compared to other antioxidants like Quercetin and Selenium on synovial fluid and these factors. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods. \r\n", "en": "Osteoarthritis (OA) is the most prevalent disorder of the musculoskeletal system and has a very high socioeconomic impact. Current treatments for Osteoarthritis are only symptomatic, because they do not act on the causes of Arthritis and do not stop the progression of the disease. This study is designed to investigate the effect of Resveratrol, Quercetin, and Selenium on special inflammation enzymes and factors in human synovial fluid. \r\nEspecially Resveratrol is known as a potent specific inhibitor of inflammation, but its potency has not been tested on human synovial fluid. If the protective potency on Osteoarthritis is similar to the results of animal experiments, it would be an enormous effort. Previous studies indicate that elevated levels of matrix metalloproteinases (MMPs) and receptor activator of nuclear factor NFkB ligand (RANKL) play an important role in cartilage degeneration in OA Rheumatic Arthritis (RA) and Psoriatic Arthritis (PsA) [1, 2]. \r\nThis study should be undertaken to define a possible influence of Resveratrol compared to other antioxidants like Quercetin and Selenium on synovial fluid and these factors. A close interaction between clinicians and basic scientists is necessary because of the combination of analytical, functional and molecular methods. \r\n" }, "begin_planned": "2009-01-01T01:00:00+01:00", "begin_effective": "2009-01-01T01:00:00+01:00", "end_planned": "2009-12-31T01:00:00+01:00", "end_effective": "2009-12-31T01:00:00+01:00", "assignment": "2009-01-15T11:27:46+01:00", "program": null, "subprogram": null, "organization": 14052, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1721-50696-12", "1721-57343-12", "1721-50826-12" ] }, { "id": 1957, "title": { "de": "Genetics of the Dopaminergic System and Smoking Behavior", "en": "Genetics of the Dopaminergic System and Smoking Behavior" }, "short": "Genetics of the Dopaminergic System", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": null, "begin_effective": "2009-01-01T01:00:00+01:00", "end_planned": null, "end_effective": "2010-12-30T01:00:00+01:00", "assignment": "2009-10-23T12:55:40+02:00", "program": null, "subprogram": null, "organization": 14028, "category": 10, "type": 10, "partner_function": 4, "manager": 50910, "contact": 50910, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1957-50910-10" ] }, { "id": 1671, "title": { "de": "Nachweis antibiotikarestistenter Escherichia coli-Stämme aus Klärschlamm unter Berücksichtigung der verschiedenen Klärschlammbehandlungsverfahren", "en": "Nachweis antibiotikarestistenter Escherichia coli-Stämme aus Klärschlamm unter Berücksichtigung der verschiedenen Klärschlammbehandlungsverfahren" }, "short": "Escherichia coli-Stämme aus Klärschlamm ", "url": null, "abstract": { "de": "Die Ausbreitung resistenter Bakterien und antibiotisch wirksamer Substanzen aus Klärschlamm in die Umwelt ist derzeit nur schwer abschätzbar.\r\nIn der vorliegenden Studie sollten antibiotikaresistente Bakterien im Zusammenhang mit unterschiedlichen Behandlungs- und Hygienisierungsverfahren von Klärschlamm untersucht werden. Dabei sollten jene unterschiedlichen Verfahren verglichen werden bei welchen einerseits bei Einhaltung der richtigen Prozessbedingungen eine Entseuchung des Klärschlammes sichergestellt wird und andererseits die konventionellen Schlammbehandlungsverfahren, z.B. die anaerobe mesophile Faulung und die aerobe Stabilisierung.", "en": "Die Ausbreitung resistenter Bakterien und antibiotisch wirksamer Substanzen aus Klärschlamm in die Umwelt ist derzeit nur schwer abschätzbar.\r\nIn der vorliegenden Studie sollten antibiotikaresistente Bakterien im Zusammenhang mit unterschiedlichen Behandlungs- und Hygienisierungsverfahren von Klärschlamm untersucht werden. Dabei sollten jene unterschiedlichen Verfahren verglichen werden bei welchen einerseits bei Einhaltung der richtigen Prozessbedingungen eine Entseuchung des Klärschlammes sichergestellt wird und andererseits die konventionellen Schlammbehandlungsverfahren, z.B. die anaerobe mesophile Faulung und die aerobe Stabilisierung." }, "begin_planned": "2009-01-01T01:00:00+01:00", "begin_effective": "2009-01-01T01:00:00+01:00", "end_planned": "2009-12-31T01:00:00+01:00", "end_effective": "2010-01-31T01:00:00+01:00", "assignment": "2008-12-04T12:26:09+01:00", "program": null, "subprogram": "Fördergeber Land Steiermark Fachabteilung 19D", "organization": 14023, "category": 10, "type": 10, "partner_function": 4, "manager": 51674, "contact": 51674, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1671-51674-10" ] }, { "id": 1722, "title": { "de": "Determining the Hierarchy of EMTRs in Malignant Melanoma", "en": "Determining the Hierarchy of EMTRs in Malignant Melanoma" }, "short": "DETERMINING_HIERARCHY_EMTR_MELANOMA", "url": null, "abstract": { "de": "Epithelial-mesenchymal transition (EMT) is a hallmark of cellular transformation in solid tumors. A similar process is thought to be relevant for melanomgenesis. The exact mechanisms how this is accomplished with respect to stage specific effects of epilthelial-mesenchymal transcriptional regulation, however, are unknown for many tumor entities and melanoma in particular. \r\nThe intent of this project is to decipher targets of EMT inducing regulators at the transcriptional level as exemplified by modulation of cadherins through hepatocyte growth factor (HGF), an important growth factor in melanomagenesis. Our previous data show that the effect of HGF on epithelial-mesenchymal transcriptional regulators (EMTRs) is stage-dependent in melanoma cell lines. Based on these observations we want to pinpoint EMTRs specific binding to E-boxes in cadherins, investigate on HGF-mediated regulation of Snail and Slug and study overexpression of Slug and Twist in melanoma cell lines. We expect to uncover the hierachical sequence of EMTRs activation in early versus late stage melanomas, the preferential binding of EMRTs to cadherins and in vitro and in vivo effects of over-expressed or down-regulated EMRTs. The following hypothesis:\r\n\"Hierachy of epithelial-mesenchymal transcriptional regulators in malignant melanoma\"\r\nwill be tested in two specific aims:\r\n*Continuing investigations on E-box binding EMRTs and the functional effects of Slug and Twist in melanocytic cells \r\n*Scrutinizing HGF mediated modulation of Snail, Slug and Twist through regulation by NF-kB and GSK -3ß.", "en": "Epithelial-mesenchymal transition (EMT) is a hallmark of cellular transformation in solid tumors. A similar process is thought to be relevant for melanomgenesis. The exact mechanisms how this is accomplished with respect to stage specific effects of epilthelial-mesenchymal transcriptional regulation, however, are unknown for many tumor entities and melanoma in particular. \r\nThe intent of this project is to decipher targets of EMT inducing regulators at the transcriptional level as exemplified by modulation of cadherins through hepatocyte growth factor (HGF), an important growth factor in melanomagenesis. Our previous data show that the effect of HGF on epithelial-mesenchymal transcriptional regulators (EMTRs) is stage-dependent in melanoma cell lines. Based on these observations we want to pinpoint EMTRs specific binding to E-boxes in cadherins, investigate on HGF-mediated regulation of Snail and Slug and study overexpression of Slug and Twist in melanoma cell lines. We expect to uncover the hierachical sequence of EMTRs activation in early versus late stage melanomas, the preferential binding of EMRTs to cadherins and in vitro and in vivo effects of over-expressed or down-regulated EMRTs. The following hypothesis:\r\n\"Hierachy of epithelial-mesenchymal transcriptional regulators in malignant melanoma\"\r\nwill be tested in two specific aims:\r\n*Continuing investigations on E-box binding EMRTs and the functional effects of Slug and Twist in melanocytic cells \r\n*Scrutinizing HGF mediated modulation of Snail, Slug and Twist through regulation by NF-kB and GSK -3ß." }, "begin_planned": "2008-08-01T02:00:00+02:00", "begin_effective": "2009-01-15T01:00:00+01:00", "end_planned": "2009-07-31T02:00:00+02:00", "end_effective": "2011-01-14T01:00:00+01:00", "assignment": "2009-01-16T14:06:24+01:00", "program": 72, "subprogram": null, "organization": 14047, "category": 10, "type": 10, "partner_function": 4, "manager": 53662, "contact": 53662, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P21156", "ethics_committee": null, "edudract_number": null, "persons": [ "1722-53662-10" ] }, { "id": 1735, "title": { "de": "GOLD3 - Genomics Of Lipid Droplet Biology, Component 8: Lipid droplet-associated proteins regulating lipid storage and release in macrophages and foam cells", "en": "GOLD3 - Genomics Of Lipid Droplet Biology, Component 8: Lipid droplet-associated proteins regulating lipid storage and release in macrophages and foam cells" }, "short": "GOLD3_KRATKY", "url": null, "abstract": { "de": "Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis.", "en": "Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis." }, "begin_planned": "2008-12-01T01:00:00+01:00", "begin_effective": "2009-02-01T01:00:00+01:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-04-30T02:00:00+02:00", "assignment": "2009-01-22T11:56:26+01:00", "program": 73, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 2, "manager": 51904, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1735-51904-10", "1735-58794-11" ] }, { "id": 1714, "title": { "de": "GOLD3 - Genomics Of Lipid Droplet Biology, Component 5: Discovery of lipolytic activities by in vivo proteomic profiling", "en": "GOLD3 - Genomics Of Lipid Droplet Biology, Component 5: Discovery of lipolytic activities by in vivo proteomic profiling" }, "short": "GOLD3_BIRNER_GRUENBERGER", "url": null, "abstract": { "de": "Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis.", "en": "Lipid-associated disorders constitute a major health treat wordlwide. Currently more than one billion individuals are overweight or obese and it is estimated that by 2010 more than 300 million patients will be affected by insulin resistance and type-II diabetes.\r\nThe general aim of GOLD 3 is to elucidate processes that govern the biology of lipid droplets (LD), their synthesis and mobilization under normal and pathological conditions.\r\nThe proposed project will discover genes, proteins, and metabolites involved in the generation and catabolsim of LD in human cells. The characterization of their biochemical function, regulation od their expression, and 3-D structure will reveal currently unknown mechanisms and pathways that control the generation of lipid signalling molecules, energy substrates and membrane components affecting cell tissue function as well as energy homeostasis." }, "begin_planned": "2008-12-01T01:00:00+01:00", "begin_effective": "2009-02-01T01:00:00+01:00", "end_planned": "2011-11-30T01:00:00+01:00", "end_effective": "2012-04-30T02:00:00+02:00", "assignment": "2009-01-14T12:15:11+01:00", "program": 73, "subprogram": null, "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": 58794, "contact": 58794, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 152 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1714-58794-10" ] }, { "id": 1723, "title": { "de": "Die Rolle von MMP12 und Angiostatin in der humanen Plazentaentwicklung bei Diabetes", "en": "Die Rolle von MMP12 und Angiostatin in der humanen Plazentaentwicklung bei Diabetes" }, "short": "MMP12 und Angiostatin", "url": null, "abstract": { "de": "Die Plazenatentwicklung ist besonders im 1. Schwangerschaftstrimenon kritisch. Trophoblastzellen wandern in den Uterus ein (Invasion), verankern die Plazenta und vergrößern uterine Blutgefäße. Das gesamte Blutgefäßsystem in Plazenta und Uterus expandiert (Angiogenese). Defekte können zu Präeklampsie, fötaler Wachstumsrestriktion oder Fehlgeburt und Pathologien mit erhöhtem Risiko bei Diabetes führen. Vorversuche zeigen, dass Traophoblasten große Mengen des Enzymes MMP12 bilden, das Plasminogen im Serum in Angiostatin spaltet. Diese hemmt Angiogenese und Invasion. In Makrophagen wird MMP12-Synthese durch in Diabetes erhöhte Faktoren (Isulin, TNF-, TGF-) erhöht. In Trophoblasten habe ich Insulin und Glukose als Stimulatoren für MMP12-Bildung identifiziert. Darum wird in diesem Projekt der Effekt von Diabetes im 1. Trimenon auf MMP12-Synthese und der Freisetzung von Angiostatin ermittelt und die Wirkung auf Angiogenese im Uterus und Plazenta sowie auf Trophoblast-Invasion untersucht.", "en": "Die Plazenatentwicklung ist besonders im 1. Schwangerschaftstrimenon kritisch. Trophoblastzellen wandern in den Uterus ein (Invasion), verankern die Plazenta und vergrößern uterine Blutgefäße. Das gesamte Blutgefäßsystem in Plazenta und Uterus expandiert (Angiogenese). Defekte können zu Präeklampsie, fötaler Wachstumsrestriktion oder Fehlgeburt und Pathologien mit erhöhtem Risiko bei Diabetes führen. Vorversuche zeigen, dass Traophoblasten große Mengen des Enzymes MMP12 bilden, das Plasminogen im Serum in Angiostatin spaltet. Diese hemmt Angiogenese und Invasion. In Makrophagen wird MMP12-Synthese durch in Diabetes erhöhte Faktoren (Isulin, TNF-, TGF-) erhöht. In Trophoblasten habe ich Insulin und Glukose als Stimulatoren für MMP12-Bildung identifiziert. Darum wird in diesem Projekt der Effekt von Diabetes im 1. Trimenon auf MMP12-Synthese und der Freisetzung von Angiostatin ermittelt und die Wirkung auf Angiogenese im Uterus und Plazenta sowie auf Trophoblast-Invasion untersucht." }, "begin_planned": "2009-02-01T01:00:00+01:00", "begin_effective": "2009-02-01T01:00:00+01:00", "end_planned": "2011-01-31T01:00:00+01:00", "end_effective": "2011-07-31T02:00:00+02:00", "assignment": "2009-01-16T14:13:41+01:00", "program": 79, "subprogram": null, "organization": 14038, "category": 10, "type": 10, "partner_function": 4, "manager": 50674, "contact": 50674, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1723-50674-10" ] }, { "id": 1820, "title": { "de": "NANO-AS: Nano-Tox-Verlängerung", "en": "NANO-AS: Nano-Tox-Verlängerung" }, "short": "NANO-AS", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T12:36:34+02:00", "program": null, "subprogram": "Nano-Health", "organization": 28394, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1821, "title": { "de": "Nano-Health: Nano-Plaque-Extension", "en": "Nano-Health: Nano-Plaque-Extension" }, "short": "Nano-Plaque-Extension", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-01-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T13:05:25+02:00", "program": null, "subprogram": "Nano-Health Verlängerung", "organization": 14028, "category": 10, "type": 10, "partner_function": 2, "manager": 52854, "contact": 52854, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1821-52854-10" ] }, { "id": 1819, "title": { "de": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo", "en": "Nano-Health: 4D Molecular Imaging of human Stem Cells in vivo" }, "short": "Nano-Health: 4D Imaging of Stem Cells", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter increasingly in relatively young patientes, call for a new healthcare model that is more proactive, i.e. that detects disease pre-symptomatically when it is more amenable to treatment, more personalised, i.e. based on the growing knowledge about the molecular mechanisms underlying disease, less traumatic and more targeted, i.e. that non-invasively or minimally invasively and specifically treats the affected tissue or organ(s) and allows more informed interventions, i.e. That enables the progress of therapy and relapse to be followed in as close to real time as possible.\r\nThe extended project will build on the achievements of NANO-HEALTH made to date. Within the first two years an NP platform based on 4 different types of NPs was elaborated and optimised for drug delivery and imaging. All NPs were characterised in detail by physico-chemical and chemical methods. Starting from this platform, the most promising NPs were optimised for oral drug delivery, for a depot formulation of Vasoactive Intestinal Peptide (VIP), for contrast media using MRI and Spect/PET and to trace stem cells in vivo and for the early detection of atherosclerotic plaque. Several proof-of-concept studies were performed from the end of year 2 up to now (3 years and 3 months).\r\n\r\nThe prolongation of NANO-HEALTH year 5 to 7 will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral and topical (depot)delivery of active substances\r\n*(Based on the successful results obtained so far) large scale production processes for nano-thiomers and PLA-HSA-based NPs\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-03-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2012-02-28T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-05-18T11:50:29+02:00", "program": null, "subprogram": "Nano-Health", "organization": 14082, "category": 10, "type": 10, "partner_function": 2, "manager": null, "contact": null, "status": 2, "research": 3, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1819-50747-12" ] }, { "id": 1716, "title": { "de": "Nano-Health: Nano-structured materials for drug targeting, release and imaging", "en": "Nano-Health: Nano-structured materials for drug targeting, release and imaging" }, "short": "NANO-HEALTH", "url": null, "abstract": { "de": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity", "en": "The increasing incidence of cancer and of degenerative diseases, the latter uncreasingly in relatively young patients, calls for a new healthcare model that is more proactive (detects asymptomatic disease when it is more amenable to treatment), more personalised (based on the growing knowledge about the molecular mechanisms underlying disease), less traumatic and more targeted (non/minimally invasively and specifically treats the affected tissue or organ(s)) and that allows more informed interventions (following of the progress of therapy and disease reoccurrence in as close to real time as possible).\r\nThis prolongation of NANO-HEALTH will build on the work done to date to develop new NM-based solutions for targeted drug delivery and imaging. The following topics will be pursued:\r\n*Further development of thiomers for oral delivery of active substances\r\n*An industrial production process for nano-thiomers\r\n*Development of targeted imaging for cancer using MRI\r\n*Stem cell tracking in vivo\r\n*Atherosclerotic plaque detection\r\n*Chronic nanotoxicity" }, "begin_planned": "2009-01-01T01:00:00+01:00", "begin_effective": "2009-03-01T01:00:00+01:00", "end_planned": "2011-12-31T01:00:00+01:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-14T14:15:30+01:00", "program": null, "subprogram": "Nano-Initiative", "organization": 28392, "category": 10, "type": 10, "partner_function": 2, "manager": 54033, "contact": null, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1716-54033-10" ] }, { "id": 2796, "title": { "de": "Anschaffung eines ultrahochauflösenden Massenspektrometrie Systems als Lipidomics und Proteomics Plattform an der Medizinischen Universität Graz. ", "en": "Anschaffung eines ultrahochauflösenden Massenspektrometrie Systems als Lipidomics und Proteomics Plattform an der Medizinischen Universität Graz. " }, "short": "EFRE- Massenspektometrie", "url": null, "abstract": { "de": "Ziel dieses Projektes ist die Anschaffung eines ultrahochauflösenden Massenspektrometers zur qualitativen und quantitativen Bestimmung von Lipiden und im Lipidstoffwechsel aktiven Enzymen, welche in Krankheitsbildern wie Metabolisches Syndrom, chronische Entzündung, Diabetes oder Atherosklerose eine entscheidende Rolle spielen. Der Vorteil von Ultrahochauflösung liegt in der daraus berechenbaren exakten Masse über welche die Identifizierungssicherheit von Lipiden und Proteinen enorm gesteigert werden kann. Als zusätzliche Selektivitätskriterien sollen Fragmentspektren und chromatographische Retentionszeiten herangezogen werden können um über Polarität und Struktur des Moleküls auf dessen Identität schließen zu können. Durch das Zusammenspiel dieser oben genannten technischen Parameter wird es möglich sein die Anzahl von bestimmbaren Lipiden und Proteinen pro Probe deutlich zu steigern. Dadurch sind wichtige Signalmoleküle die in geringsten Mengen im Organismus vorkommen und deshalb für die molekulare Grundlagenforschung von ganz besonderem Interesse sind auch erfassbar.\r\nDie Lipidforschung in Graz und an der MUG genießt Weltruf und ist ein verbindendes Element zwischen allen Grazer akademischen Institutionen. Durch den technologischen Fortschritt im Bereich der Massenspektrometrie wurde es in der letzten Dekade möglich immer detailiertere Informationen über das molekulare Geschehen in biologischen Systemen auf Ebene von Lipiden und Proteinen zu gewinnen. Die daraus entstandenen Begriffe Lipidomics und Proteomics sind die deskriptive Erforschung der Gesamtheit aller Lipide und Proteine in einem definierten biologischen System. Die Basis dieser neuen omics Wissenschaften sind massenspektrometrische Systeme welche im Zuge des technologischen Fortschritts immer empfindlicher und schneller (High Throughput) werden, sowie eine immer höhere Massenauflösung bieten. Diese Faktoren sind die Grundlage um möglichst viele Lipide und Proteine in kurzer Zeit mit hoher Treffsicherheit bestimmen zu können, vor allem auch jene Spezies welche zwar in äußerst geringer Konzentration in zellulären Systemen vorkommen, aber häufig sehr großen Einfluss auf Signalübertragungsprozesse haben. \r\nIm Bereich der Lipide geht die Schätzung natürlich vorkommender molekularer Spezies auf weit über 100.000 wovon bisher knapp 10.000 beschrieben und in Datenbanken erfasst sind. Für die Identifizierung und Charakterisierung zusätzlicher Substanzen ist ultrahochauflösende Massenspektrometrie aufgrund der mit dieser Eigenschaft einhergehenden hohen Konfidenz mittlerweile ein unverzichtbares Werkzeug geworden. Aber auch die Quantifizierung des bereits in Datenbanken erfassten Lipidoms in allen seinen Einzelbausteinen ist für Forschungsprojekte der MUG im 21. Jahrhundert die deskriptive Grundlage auf der Hypothesen über zelluläre Mechanismen des Fettstoffwechsels aufgebaut und in weiterer Folge verifiziert oder auch falsifiziert werden. \r\nMit dem in Graz entwickelten System der Activity based Proteomics ist es möglich am Lipidstoffwechsel beteiligte Enzyme (Lipasen) über Fluoreszenzlabeling und Massenspektrometrie zielgenau zu identifizieren. Da viele Lipasen in geringsten Mengen vorkommen ist es auch hier essentiell, möglichst hohe Identitätssicherheit mit maximaler analytischer Empfindlichkeit zu kombinieren. Mit diesem System wird es möglich sein auch in Zukunft neue regulatorische Schlüsselstellen des Lipidstoffwechsels sichtbar und der medizinischen Weiterverwertung zugänglich zu machen.\r\n\r\n", "en": "Ziel dieses Projektes ist die Anschaffung eines ultrahochauflösenden Massenspektrometers zur qualitativen und quantitativen Bestimmung von Lipiden und im Lipidstoffwechsel aktiven Enzymen, welche in Krankheitsbildern wie Metabolisches Syndrom, chronische Entzündung, Diabetes oder Atherosklerose eine entscheidende Rolle spielen. Der Vorteil von Ultrahochauflösung liegt in der daraus berechenbaren exakten Masse über welche die Identifizierungssicherheit von Lipiden und Proteinen enorm gesteigert werden kann. Als zusätzliche Selektivitätskriterien sollen Fragmentspektren und chromatographische Retentionszeiten herangezogen werden können um über Polarität und Struktur des Moleküls auf dessen Identität schließen zu können. Durch das Zusammenspiel dieser oben genannten technischen Parameter wird es möglich sein die Anzahl von bestimmbaren Lipiden und Proteinen pro Probe deutlich zu steigern. Dadurch sind wichtige Signalmoleküle die in geringsten Mengen im Organismus vorkommen und deshalb für die molekulare Grundlagenforschung von ganz besonderem Interesse sind auch erfassbar.\r\nDie Lipidforschung in Graz und an der MUG genießt Weltruf und ist ein verbindendes Element zwischen allen Grazer akademischen Institutionen. Durch den technologischen Fortschritt im Bereich der Massenspektrometrie wurde es in der letzten Dekade möglich immer detailiertere Informationen über das molekulare Geschehen in biologischen Systemen auf Ebene von Lipiden und Proteinen zu gewinnen. Die daraus entstandenen Begriffe Lipidomics und Proteomics sind die deskriptive Erforschung der Gesamtheit aller Lipide und Proteine in einem definierten biologischen System. Die Basis dieser neuen omics Wissenschaften sind massenspektrometrische Systeme welche im Zuge des technologischen Fortschritts immer empfindlicher und schneller (High Throughput) werden, sowie eine immer höhere Massenauflösung bieten. Diese Faktoren sind die Grundlage um möglichst viele Lipide und Proteine in kurzer Zeit mit hoher Treffsicherheit bestimmen zu können, vor allem auch jene Spezies welche zwar in äußerst geringer Konzentration in zellulären Systemen vorkommen, aber häufig sehr großen Einfluss auf Signalübertragungsprozesse haben. \r\nIm Bereich der Lipide geht die Schätzung natürlich vorkommender molekularer Spezies auf weit über 100.000 wovon bisher knapp 10.000 beschrieben und in Datenbanken erfasst sind. Für die Identifizierung und Charakterisierung zusätzlicher Substanzen ist ultrahochauflösende Massenspektrometrie aufgrund der mit dieser Eigenschaft einhergehenden hohen Konfidenz mittlerweile ein unverzichtbares Werkzeug geworden. Aber auch die Quantifizierung des bereits in Datenbanken erfassten Lipidoms in allen seinen Einzelbausteinen ist für Forschungsprojekte der MUG im 21. Jahrhundert die deskriptive Grundlage auf der Hypothesen über zelluläre Mechanismen des Fettstoffwechsels aufgebaut und in weiterer Folge verifiziert oder auch falsifiziert werden. \r\nMit dem in Graz entwickelten System der Activity based Proteomics ist es möglich am Lipidstoffwechsel beteiligte Enzyme (Lipasen) über Fluoreszenzlabeling und Massenspektrometrie zielgenau zu identifizieren. Da viele Lipasen in geringsten Mengen vorkommen ist es auch hier essentiell, möglichst hohe Identitätssicherheit mit maximaler analytischer Empfindlichkeit zu kombinieren. Mit diesem System wird es möglich sein auch in Zukunft neue regulatorische Schlüsselstellen des Lipidstoffwechsels sichtbar und der medizinischen Weiterverwertung zugänglich zu machen.\r\n\r\n" }, "begin_planned": null, "begin_effective": "2009-03-29T01:00:00+01:00", "end_planned": null, "end_effective": "2011-03-31T02:00:00+02:00", "assignment": null, "program": null, "subprogram": "EFRE", "organization": 17225, "category": 10, "type": 10, "partner_function": 4, "manager": 58794, "contact": 58794, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10, 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2796-58794-10" ] }, { "id": 1732, "title": { "de": "Zerebrale und peripher-muskuläre Gewebssättigung unmittelbar nach der Geburt [Postpartale zerebrale und periphere Oxygenierung bei reifen Neugeborenen und Frühgeborenen]", "en": "Transition after birth: cerebral and peripheral muscle oxygenation in term and preterm neonates" }, "short": "Oxygenierung", "url": null, "abstract": { "de": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring.", "en": "Mit Nah-Infrarot Spektroskopie (NIRS) kann die Oxygenierung in verschiedenen Gewebsregionen gemessen werden. Zahlreiche Studien bei reifen Neugeborenen und Frühgeborenen wurden bereits durchgeführt, wobei es jedoch noch keine Daten der zerebralen und peripher-muskulären Oxygenierung unmittelbar nach der Geburt gibt. \r\nZiel der vorliegenden Studie ist es daher, die zerebrale und peripher-muskuläre Oxygenierung unmittelbar nach der Geburt mit NIRS zu messen und zu analysieren. Sollte eine Atemunterstützung mit Maske notwendig sein, wird der Einfluss von \"continuous positive airway pressure\" (CPAP) oder \"positive pressure ventilation\" (PPV) analysiert. Das Studiendesign ist prospektiv beobachtend.\r\nNIRS wird kombiniert mit nicht-invasivem Monitoring der arteriellen Sauerstoffsättigung, der Herzfrequenz, der Hämoglobinkonzentration, des Blutdrucks, mit einer Videodokumentation und -bei Atemunterstützung mit CPAP oder PPV- mit einem Atemfunktionsmonitoring." }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2011-03-31T02:00:00+02:00", "end_effective": "2012-02-28T01:00:00+01:00", "assignment": "2009-01-19T12:54:11+01:00", "program": 79, "subprogram": null, "organization": 14094, "category": 10, "type": 10, "partner_function": 4, "manager": 50907, "contact": 50907, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 12 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1732-50907-10" ] }, { "id": 2008, "title": { "de": "Ganganalysen bei Kindern mit Morbus Perthes", "en": "Ganganalysen bei Kindern mit Morbus Perthes" }, "short": "Morbus Perthes", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-04-01T02:00:00+02:00", "begin_effective": "2009-04-01T02:00:00+02:00", "end_planned": "2009-08-31T02:00:00+02:00", "end_effective": "2012-07-31T02:00:00+02:00", "assignment": "2009-12-04T11:57:57+01:00", "program": null, "subprogram": "Land Steiermark Abteilung 3", "organization": 14049, "category": 10, "type": 10, "partner_function": 4, "manager": 65038, "contact": 65038, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2008-65038-10" ] }, { "id": 1931, "title": { "de": "Expression der Glykoproteine B7-H1 und B7-H3 auf Tumorzellen von Patienten mit metastasiertem, klarzelligem Nierenzellkarzinom. Einfluss der Glykoproteine auf die Prognose", "en": "Expression der Glykoproteine B7-H1 und B7-H3 auf Tumorzellen von Patienten mit metastasiertem, klarzelligem Nierenzellkarzinom. Einfluss der Glykoproteine auf die Prognose" }, "short": "Expression der Glykoproteine B7-H3", "url": null, "abstract": { "de": "Das metastasierte Nierenzellkarzinom ist ein aggressiver Tumor der weder strahlen- noch chemosensibel ist. Auftretende singuläre Metastasen werden wenn möglich immer chirurgisch entfernt. Bei multipler Metastasierung kommt eine Immuntherapie sowie eine Anti-angiogenetische Therapie oder auch eine Kombination aus beiden zur Anwendung. In den letzten 20 Jahren war die Immuntherapie die einzig erfolgreiche Therapie bei diesen Patienten. In den letzten Jahren wurden eine Reihe von co-inhibitorischen und co-stimulatorischen Molekülen auf Zellen des Immunsystems aber auch auf Tumorzellen gefunden. Diese Moleküle können einzelne Zellen im Immunsystem blockieren oder aber stimulieren.\r\nWir glauben, dass Patienten die die co-inhibitorischen Moleküle B7-H1 und B7-H3 an ihrer Oberfläche exprimieren, eine unterdrückte Immunabwehr haben und, dass diese Patienten aus diesem Grund schlecht auf einen Immuntherapie ansprechen und früher versterben. \r\nUnser Ziel ist es, das Gewebe aller Patienten die wir in den letzten 15 Jahren mit einer Immuntherapie behandelt haben zu färben und zu evaluieren ob sie B7-H1 und B7-H3 exprimieren.\r\nEs wäre von großem Vorteil Patienten von vornherein identifizieren zu können, die auf eine Immuntherapie ansprechen. Dadurch könnte den Patienten die nicht ansprechen von vornherein eine oft recht nebenwirkungsreiche Therapie erspart werden.", "en": "Das metastasierte Nierenzellkarzinom ist ein aggressiver Tumor der weder strahlen- noch chemosensibel ist. Auftretende singuläre Metastasen werden wenn möglich immer chirurgisch entfernt. Bei multipler Metastasierung kommt eine Immuntherapie sowie eine Anti-angiogenetische Therapie oder auch eine Kombination aus beiden zur Anwendung. In den letzten 20 Jahren war die Immuntherapie die einzig erfolgreiche Therapie bei diesen Patienten. In den letzten Jahren wurden eine Reihe von co-inhibitorischen und co-stimulatorischen Molekülen auf Zellen des Immunsystems aber auch auf Tumorzellen gefunden. Diese Moleküle können einzelne Zellen im Immunsystem blockieren oder aber stimulieren.\r\nWir glauben, dass Patienten die die co-inhibitorischen Moleküle B7-H1 und B7-H3 an ihrer Oberfläche exprimieren, eine unterdrückte Immunabwehr haben und, dass diese Patienten aus diesem Grund schlecht auf einen Immuntherapie ansprechen und früher versterben. \r\nUnser Ziel ist es, das Gewebe aller Patienten die wir in den letzten 15 Jahren mit einer Immuntherapie behandelt haben zu färben und zu evaluieren ob sie B7-H1 und B7-H3 exprimieren.\r\nEs wäre von großem Vorteil Patienten von vornherein identifizieren zu können, die auf eine Immuntherapie ansprechen. Dadurch könnte den Patienten die nicht ansprechen von vornherein eine oft recht nebenwirkungsreiche Therapie erspart werden." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2009-07-01T02:00:00+02:00", "end_effective": "2010-12-31T01:00:00+01:00", "assignment": "2009-09-22T13:07:22+02:00", "program": null, "subprogram": null, "organization": 14056, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 1882, "title": { "de": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer", "en": "Analysis of drug-metabolizing enzyme polymorphisms for response to anthracycline-based neoadjuvant chemotherapy in breast cancer" }, "short": "CHEMOTHERAP_BREAST CANCER", "url": null, "abstract": { "de": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis.", "en": "Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer-related death in Europe and the United States. Despite several improvements in early diagnosis, surgical techniques and hormone-, immune- and chemotherapy, this disease remains a threat to life for a large number of women. Moreover, providing individual treatment with low toxicity but maximum benefit is still an unsolved problem.\r\nNeoadjuvant chemotherapy using anthracycline-containing regimes is a standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease. The main goal of neoadjuvant chemotherapy is to eliminate potential micrometastasis, thus improving disease-free survial.\r\nPharmacogenetics is aimed at understanding and predicting an individual's drug response based upon genetic variation.\r\n\r\nIn this pharmacogenetic project we investigate a set of heritable genetic factors in drug-metabolizing enzymes that might predict drug-induced anti-tumor response and toxicity of anthracycline-based neoadjuvant therapy in breast cancer, based upon multigenetic analysis." }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2009-09-30T02:00:00+02:00", "end_effective": "2010-09-30T02:00:00+02:00", "assignment": "2009-08-03T14:52:33+02:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": 58814, "contact": 58814, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "1882-58814-10" ] }, { "id": 2151, "title": { "de": "Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark", "en": "Entwicklung eines praktikablen Werkzeugs für die Bewertung und Implementierung evidenzbasierter Leitlinien in Kooperation mit den Krankenhäusern in der Steiermark" }, "short": "EVIDENZBASIERTE LEITLINIEN", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-01T02:00:00+02:00", "begin_effective": "2009-05-01T02:00:00+02:00", "end_planned": "2011-04-30T02:00:00+02:00", "end_effective": "2011-04-30T02:00:00+02:00", "assignment": "2010-03-04T12:31:15+01:00", "program": null, "subprogram": null, "organization": 14026, "category": 10, "type": 10, "partner_function": 4, "manager": 51098, "contact": 51098, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2151-51098-10" ] }, { "id": 2398, "title": { "de": "SIMNET STYRIA 2009/2010", "en": "SIMNET STYRIA 2009/2010" }, "short": "SIMNET", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-05-18T02:00:00+02:00", "begin_effective": "2009-05-18T02:00:00+02:00", "end_planned": "2011-05-31T02:00:00+02:00", "end_effective": "2011-05-31T02:00:00+02:00", "assignment": "2011-02-07T14:48:55+01:00", "program": null, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 2, "manager": 50966, "contact": 50966, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2398-50966-10" ] }, { "id": 1956, "title": { "de": "Schlaganfallrisikofaktoren in der Grazer Bevölkerung: Was bewirkt eine wiederholte Vorsorgeuntersuchung? Ergebnisse der Austrian Stroke Prevention Study", "en": "Schlaganfallrisikofaktoren in der Grazer Bevölkerung: Was bewirkt eine wiederholte Vorsorgeuntersuchung? Ergebnisse der Austrian Stroke Prevention Study" }, "short": "SCHLAGANFALLRISIKO_GRAZER_BEVOELK", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-06-01T02:00:00+02:00", "begin_effective": "2009-06-01T02:00:00+02:00", "end_planned": "2010-09-30T02:00:00+02:00", "end_effective": "2010-09-30T02:00:00+02:00", "assignment": "2009-10-22T19:32:12+02:00", "program": null, "subprogram": null, "organization": 14051, "category": 10, "type": 10, "partner_function": 4, "manager": null, "contact": null, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [] }, { "id": 2169, "title": { "de": "Zytokin-vermittelte neuronale Differenzierung endogener Stammzellen im Gyrus dentatus des Hippocampus", "en": "Zytokin-vermittelte neuronale Differenzierung endogener Stammzellen im Gyrus dentatus des Hippocampus" }, "short": "ZYTOKIN_HIPPOCAMPUS", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2009-06-01T02:00:00+02:00", "begin_effective": "2009-06-01T02:00:00+02:00", "end_planned": "2010-05-31T02:00:00+02:00", "end_effective": "2010-05-31T02:00:00+02:00", "assignment": "2010-04-08T15:07:58+02:00", "program": null, "subprogram": null, "organization": 14050, "category": 10, "type": 10, "partner_function": null, "manager": 63490, "contact": 63490, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "2169-63490-10" ] } ] }